Dose-Escalation Study of PHA-793887 in Patients With Advanced/Metastatic Solid Tumors

Inclusion Criteria: * Advanced/metastatic solid tumors for which no standard therapy exists * ECOG (WHO) performance status 0-1 * Life expectancy of at least 3 months * Age ≥ 18 years * Adequate liver, pancreas and renal function * Acceptable hematologic status * Acute toxic effects from prior therapy must be resolved to NCI CTCAE Grade ≤ 1 * Treatment with surgery, chemotherapy, or investigational therapy must be completed at least one month prior to treatment initiation (6 weeks for nitrosoureas or Mitomycin C and liposomal doxorubicin) * Prior radiation therapy allowed in no more than 25% of bone marrow reserve * Men and women of child-producing potential must agree upon the use of effective contraceptive methods Exclusion Criteria: * In the past 6 months: myocardial infarction, unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein thrombosis * Known brain metastases * Major surgery, other than diagnostic surgery, within 4 weeks prior to Day 1 * Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy * Pregnant or breast feeding women * Known infection with HIV, active hepatitis B or hepatitis C * Patients who have exhibited allergic reactions to a similar structural compound, biological agent, or formulation * History of pancreatitis or disorders making the patient at risk of pancreatitis * Previous history or current presence of neurological disorders * Patients with pre-existing symptoms of peripheral neuropathy not related to prior anticancer therapy(ies) * Concomitant treatment that may be associated with peripheral neuropathy * Other severe concurrent conditions that could compromise protocol objectives.